Selected article for: "causative agent and clinical outcome"
Author: Rowaiye, Adekunle Babajide; Okpalefe, Okiemute Ajiroghene; Onuh Adejoke, Olukemi; Ogidigo, Joyce Oloaigbe; Hannah Oladipo, Oluwakemi; Ogu, Amoge Chidinma; Oli, Angus Nnamdi; Olofinase, Samson; Onyekwere, Onyekachi; Rabiu Abubakar, Abdullahi; Jahan, Dilshad; Islam, Salequl; Dutta, Siddhartha; Haque, Mainul
Title: Attenuating the Effects of Novel COVID-19 (SARS-CoV-2) Infection-Induced Cytokine Storm and the Implications
  • Cord-id: 9tbdwgcg
  • Document date: 2021_4_16
    • ID: 9tbdwgcg
    Snippet: The COVID-19 pandemic constitutes an arduous global health challenge, and the increasing number of fatalities calls for the speedy pursuit of a remedy. This review emphasizes the changing aspects of the COVID-19 disease, featuring the cytokine storm’s pathological processes. Furthermore, we briefly reviewed potential therapeutic agents that may modulate and alleviate cytokine storms. The literature exploration was made using PubMed, Embase, MEDLINE, Google scholar, and China National Knowledge
    Document: The COVID-19 pandemic constitutes an arduous global health challenge, and the increasing number of fatalities calls for the speedy pursuit of a remedy. This review emphasizes the changing aspects of the COVID-19 disease, featuring the cytokine storm’s pathological processes. Furthermore, we briefly reviewed potential therapeutic agents that may modulate and alleviate cytokine storms. The literature exploration was made using PubMed, Embase, MEDLINE, Google scholar, and China National Knowledge Infrastructure databases to retrieve the most recent literature on the etiology, diagnostic markers, and the possible prophylactic and therapeutic options for the management of cytokine storm in patients hospitalized with COVID-19 disease. The causative agent, severe acute respiratory coronavirus-2 (SARS-CoV-2), continually threatens the efficiency of the immune system of the infected individuals. As the first responder, the innate immune system provides primary protection against COVID-19, affecting the disease’s progression, clinical outcome, and prognosis. Evidence suggests that the fatalities associated with COVID-19 are primarily due to hyper-inflammation and an aberrant immune function. Accordingly, the magnitude of the release of pro-inflammatory cytokines such as interleukin (IL)-1, (IL-6), and tumor necrosis alpha (TNF-α) significantly differentiate between mild and severe cases of COVID-19. The early prediction of a cytokine storm is made possible by several serum chemistry and hematological markers. The prompt use of these markers for diagnosis and the aggressive prevention and management of a cytokine release syndrome is critical in determining the level of morbidity and fatality associated with COVID-19. The prophylaxis and the rapid treatment of cytokine storm by clinicians will significantly enhance the fight against the dreaded COVID-19 disease.

    Search related documents:
    Co phrase search for related documents
    • acute ards respiratory distress syndrome and adaptive immune system: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and adhesion molecule: 1, 2, 3, 4, 5, 6
    • acute ards respiratory distress syndrome and adjunctive therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute ards respiratory distress syndrome and liver cell: 1, 2
    • acute ards respiratory distress syndrome and liver damage: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute ards respiratory distress syndrome and liver damage cause: 1, 2
    • acute ards respiratory distress syndrome and liver disease absence: 1
    • acute ards respiratory distress syndrome and living cell: 1
    • acute ards respiratory distress syndrome and low respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28
    • acute ards respiratory distress syndrome and low respiratory system: 1, 2, 3
    • acute ards respiratory distress syndrome and lung disease cardiovascular disease: 1, 2, 3
    • acute ards respiratory distress syndrome and lung disease cardiovascular disease diabetes: 1, 2
    • acute ards respiratory distress syndrome and lung disease cardiovascular disease diabetes hypertension: 1, 2
    • acute ards respiratory distress syndrome and lung fever: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and lung macrophage: 1, 2, 3, 4, 5, 6, 7, 8
    • acute ards respiratory distress syndrome and luteolin quercetin: 1
    • acute ards respiratory distress syndrome and lymphocyte dysfunction: 1
    • acute ards respiratory distress syndrome and lymphocyte function: 1
    • acute ards respiratory distress syndrome and lymphocyte monocyte: 1